in an effort to augment the ex vivo generation of such cells preactivated in vivo , we examined the proliferative responses of pbmc from il-2-treated cancer patients to several proliferative signals including il-2 , interleukin 4 ( il-4 ) , and mitogenic antibodies to cd3 and cd28 .
C0007634
the
C1321301
pbmc